Neoadjuvant Chemoradiation Therapy Followed by Extrafascial Hysterectomy in Locally Advanced Type II Endometrial Cancer Clinically Extending to Cervix.

[1]  Anne Wallace,et al.  Positive Surgical Margins in the 10 Most Common Solid Cancers , 2018, Scientific Reports.

[2]  A. Secord,et al.  Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Beriwal,et al.  Locally Advanced Uterine Cancer: A Multimodality Model or Muddle? , 2018, International journal of radiation oncology, biology, physics.

[4]  R. Wenham,et al.  New therapies for advanced, recurrent, and metastatic endometrial cancers , 2017, Gynecologic Oncology Research and Practice.

[5]  S. Beriwal,et al.  Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria , 2017, International Journal of Gynecologic Cancer.

[6]  J. Weedon,et al.  Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: a retrospective cohort study. , 2015, International journal of surgery.

[7]  S. Beriwal,et al.  Extended field intensity modulated radiation therapy with concomitant boost for lymph node-positive cervical cancer: analysis of regional control and recurrence patterns in the positron emission tomography/computed tomography era. , 2014, International journal of radiation oncology, biology, physics.

[8]  C. Houser,et al.  Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. , 2014, Gynecologic oncology.

[9]  Tina A. Ayeni,et al.  Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas. , 2013, Gynecologic oncology.

[10]  C. Haie-meder,et al.  Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  R. Barakat,et al.  The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. , 2011, Gynecologic oncology.

[12]  G. Shukla,et al.  Preoperative high dose rate brachytherapy for clinical stage II endometrial carcinoma , 2011, Journal of contemporary brachytherapy.

[13]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[14]  P. Gehrig,et al.  Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[15]  A. Olawaiye,et al.  Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. , 2009, Gynecologic oncology.

[16]  D. Mutch,et al.  Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. , 2008, Gynecologic oncology.

[17]  A. Mariani,et al.  Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. , 2007, Gynecologic oncology.

[18]  B. Gilks,et al.  Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. , 2005, Gynecologic oncology.

[19]  P. Boyle,et al.  Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. , 2004, Gynecologic oncology.

[20]  P. Wang,et al.  Urinary tract dysfunction after radical hysterectomy for cervical cancer. , 2002, Gynecologic oncology.

[21]  E. Sartori,et al.  Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy , 2001, International Journal of Gynecologic Cancer.

[22]  M. J. Webb,et al.  Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. , 2001, Gynecologic oncology.

[23]  R. Bentley,et al.  Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. , 1999, Gynecologic oncology.

[24]  A. Weaver,et al.  Modified radical hysterectomy: morbidity and mortality. , 1995, Gynecologic oncology.

[25]  M. Mohiuddin,et al.  Preoperative radiation therapy in clinical stage II endometrial carcinoma. , 1992, Gynecologic oncology.

[26]  V. Rantanen,et al.  Radiation sensitivity of endometrial carcinoma in vitro. , 1992, Gynecologic oncology.

[27]  R. Pearcey,et al.  Inherent radiosensitivity testing of tumor biopsies obtained from patients with carcinoma of the cervix or endometrium. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[28]  O. Yalcin,et al.  The effects of simple and radical hysterectomy and radiotherapy on lower urinary tract symptoms and urodynamics. , 2013, European journal of gynaecological oncology.

[29]  L. Delclos,et al.  Treatment of endometrial carcinoma with radiation therapy alone. , 1993, International journal of radiation oncology, biology, physics.